Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11172336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of STATs in transcriptional control and their impact on cellular function

  2000cited by this paper
• Activation of the human p27(Kip1) promoter by IFNalpha 2b.

  2000cited by this paper
• The National Cancer Data Base report on treatment patterns for hepatocellular carcinomas

  2000cited by this paper
• Antiviral therapy of HBV- and HCV-induced liver cirrhosis.

  2000cited by this paper
• Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

  2000cited by this paper
• Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells.

  2000cited by this paper
• Benefit of interferon-alpha2b in a patient with unresectable hepatoma and chronic infection with hepatitis C virus.

  2000cited by this paper
• Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

  2000cited by this paper
• Ginsenoside-Rs3, a new diol-type ginseng saponin, selectively elevates protein levels of p53 and p21WAF1 leading to induction of apoptosis in SK-HEP-1 cells.

  1999cited by this paper
• High frequency of p16INK4A gene alterations in hepatocellular carcinoma

  1999cited by this paper
• Inhibition of DNA synthesis by downregulation of cyclin A but not Skp 2 overexpression in human hepatocellular carcinoma cells.

  1999cited by this paper
• Aflatoxin and liver cancer.

  1999cited by this paper
• Mutational analysis of p73 and p53 in human cancer cell lines

  1999cited by this paper
• Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via fas‐dependent and fas‐independent pathways

  1999cited by this paper
• Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

  1999cited by this paper
• Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.

  1999cited by this paper
• Genetic Aspects of Hepatocellular Carcinogenesis

  1999cited by this paper
• Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins

  1999cited by this paper
• CDK inhibitors: positive and negative regulators of G1-phase progression.

  1999cited by this paper
• Molecular aspects of hepatocellular carcinoma.

  1999cited by this paper
• Ginsenoside-Rs4, a new type of ginseng saponin concurrently induces apoptosis and selectively elevates protein levels of p53 and p21WAF1 in human hepatoma SK-HEP-1 cells.

  1999cited by this paper
• Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor.

  1999cited by this paper
• Hepatitis C Virus and Hepatocellular Carcinoma

  1999cited by this paper
• Hepatitis C and alcohol.

  1999cited by this paper
• Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)

  1998cited by this paper
• The p16INK4a/CDKN2A tumor suppressor and its relatives.

  1998cited by this paper
• Differential Myeloma Cell Responsiveness to Interferon-α Correlates with Differential Induction of p19INK4d and Cyclin D2 Expression*

  1998cited by this paper
• Interferon-α-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages

  1998cited by this paper
• Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

  1998cited by this paper
• Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

  1998cited by this paper
• Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

  1998cited by this paper
• Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

  1998cited by this paper
• Determinants of outcome of compensated hepatitis C virus‐related cirrhosis

  1998cited by this paper
• Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma.

  1998cited by this paper
• How does interferon exert its cell growth inhibitory effect?

  1997cited by this paper
• Hyperphosphorylation of the N-terminal Domain of Cdc25 Regulates Activity toward Cyclin B1/Cdc2 But Not Cyclin A/Cdk2*

  1997cited by this paper
• Interferon-beta induces S phase accumulation selectively in human transformed cells.

  1997cited by this paper
• A Role for the Cyclin-Dependent Kinase Inhibitor p21 in the G1 Cell Cycle Arrest Mediated by the Type I Interferons

  1997cited by this paper
• Long‐term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa

  1997cited by this paper
• Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines.

  1997cited by this paper
• Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death

  1997cited by this paper
• Effect of cyclins and Cdks on the cyclin B1 promoter activation

  1997cited by this paper
• TP53 and hepatocellular carcinoma.

  1997cited by this paper
• Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.

  1996cited by this paper
• Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts.

  1996cited by this paper
• Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest

  1996cited by this paper
• Inactivation of p16INK4 in hepatocellular carcinoma

  1996cited by this paper
• The Janus protein tyrosine kinase family and its role in cytokine signaling.

  1995cited by this paper
• Characteristic difference of hepatocellular carcinoma between hepatitis B‐ and C‐ viral infection in Japan

  1995cited by this paper
• Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

  1995cited by this paper
• Cytokine therapeutics: lessons from interferon alpha.

  1994cited by this paper
• Mutations and altered expression of p16INK4 in human cancer.

  1994cited by this paper
• Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells.

  1994cited by this paper
• Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells

  1993cited by this paper
• Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation.

  1992cited by this paper
• Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma.

  1992cited by this paper
• Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells.

  1992cited by this paper
• Cyclin A is required in S phase in normal epithelial cells.

  1992cited by this paper
• cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2.

  1991cited by this paper
• p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells.

  1991cited by this paper
• Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein

  1991cited by this paper
• Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma

  1990cited by this paper
• Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.

  1990cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

  1989cited by this paper
• Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

  1989cited by this paper
• Effect of interferon-beta on the cell cycle of human glioma cell line U-251 MG: flow cytometric two-dimensional (BrdU/DNA) analysis.

  1988cited by this paper
• Virus interference. I. The interferon

  1987cited by this paper
• Inhibition of cell division by interferon: changes in cell cycle characteristics and in morphology of Ehrlich ascites tumour cells in culture.

  1981cited by this paper
• Block of a glioma cell line in S by interferon

  1981cited by this paper
• Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon.

  1980cited by this paper
• Relationship between the enhanced expression of histocompatibility antigens on interferon‐treated L 1210 cells and their position in the cell cycle

  1976cited by this paper

• Short-term exposure with high-dose interferon-α induces apoptosis in neuroblastoma cells in G0/G1 phase of the cell-cycle.

  2025cites this paper
• Signaling molecules in the microenvironment of hepatocellular carcinoma

  2024cites this paper
• Tumour cells can escape antiproliferative pressure by interferon-β through immunoediting of interferon receptor expression

  2023cites this paper
• Comparison of postoperative outcomes in cases achieving sustained virological response with direct‐acting antiviral and interferon therapy

  2023cites this paper
• Recent Progress in Interferon Therapy for Myeloid Malignancies

  2021cites this paper
• circSVIL regulates bovine myoblast development by inhibiting STAT1 phosphorylation

  2021cites this paper
• Fetal cytokine response to porcine reproductive and respiratory syndrome virus-2 infection.

  2020cites this paper
• An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population.

  2018cites this paper
• Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy

  2017cites this paper
• Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression

  2017cites this paper
• Interferon-α Acts on the S/G2/M Phases to Induce Apoptosis in the G1 Phase of an IFNAR2-expressing Hepatocellular Carcinoma Cell Line*

  2014cites this paper
• Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation.

  2014cites this paper
• Microsoft Word-maeda_manuscript_revision2

  2014cites this paper
• Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

  2013cites this paper
• Reduction of cell viability induced by IFN-alpha generates impaired data on antiviral assay using Hep-2C cells.

  2013cites this paper
• UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines

  2013cites this paper
• ISG15 Inhibits IFN-α-Resistant Liver Cancer Cell Growth

  2013cites this paper
• Type I interferons: ancient peptides with still under-discovered anti-cancer properties.

  2013cites this paper
• Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.

  2012cites this paper
• Interferons induce the expression of IFITM1 and IFITM3 and suppress the proliferation of rat neonatal cardiomyocytes

  2012cites this paper
• Therapeutic efficacy of combination therapy with intra‐arterial 5‐fluorouracil and systemic pegylated interferon α‐2b for advanced hepatocellular carcinoma with portal venous invasion

  2012cites this paper
• Title A garlic derivative , s-allylcysteine ( sac ) , suppresses proliferationand metastasis of hepatocellular carcinoma

  2012cites this paper
• A Garlic Derivative, S-allylcysteine (SAC), Suppresses Proliferation and Metastasis of Hepatocellular Carcinoma

  2012cites this paper
• Reactive Oxygen Species Act as Signaling Molecules in Liver Carcinogenesis

  2012cites this paper
• Direct anti‐cancer effect of oncostatin M on chondrosarcoma

  2011cites this paper
• STAT1 and pathogens, not a friendly relationship

  2010cites this paper
• Novel Fusion Proteins of Interferon α2b Cause Growth Inhibition and Induce JAK-STAT Signaling in Melanoma

  2010cites this paper
• Molecular bases of liver cancer refractoriness to pharmacological treatment.

  2010cites this paper
• Investigating the role of novel fusion proteins of interferon in melanoma

  2010cites this paper
• Apoptosis of human hepatocellular carcinoma cell (HepG2) induced by cardiotoxin III through S-phase arrest.

  2009cites this paper
• Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

  2009cites this paper
• Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5‐fluorouracil combined with interferon‐α in a hemodialysis patient

  2009cites this paper
• IRF9 is a Key Factor for Eliciting the Antiproliferative Activity of IFN-α

  2009cites this paper
• Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis

  2009cites this paper
• Temporal treatment with interferon-beta prevents hepatocellular carcinoma in hepatitis B virus X gene transgenic mice.

  2008cites this paper
• Saccharomyces cerevisiae, the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice

  2008cites this paper
• In Vivo Tumor Inhibitory Effects of Nutritional Rice Bran Supplement MGN-3/Biobran on Ehrlich Carcinoma-Bearing Mice

  2008cites this paper
• Type I interferon prolongs cell cycle progression via p21WAF1/CIP1 induction in human colon cancer cells.

  2007cites this paper
• ADENOSINE DEAMINASE ACTING ON RNA 1 ACCELERATES CELL CYCLE THROUGH INCREASED TRANSLATION AND ACTIVITY OF CYCLIN-DEPENDENT KINASE 2

  2007cites this paper
• Combined intra‐arterial 5‐fluorouracil and subcutaneous interferon‐alpha therapy for highly advanced hepatocellular carcinoma

  2007cites this paper
• Involvement of reactive oxygen species on the apoptotic mechanism induced by IFN-alpha2b in rat preneoplastic liver.

  2007cites this paper
• Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo.

  2007cites this paper
• Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C

  2007influential citation
• Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons.

  2007cites this paper
• Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation

  2007cites this paper
• Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

  2007cites this paper
• Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma

  2006cites this paper
• Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.

  2006cites this paper
• P48 is a predictive marker for outcome of postoperative interferon‐α treatment in patients with hepatitis B virus infection‐related hepatocellular carcinoma

  2006cites this paper
• Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment

  2006cites this paper
• A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines.

  2006cites this paper
• Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo

  2006cites this paper
• A comparison of the antitumor effects of interferon-α and β on human hepatocellular carcinoma cell lines

  2006cites this paper
• Interferonbeta-induced changes in metallothionein expression and subcellular distribution of zinc in HepG2 cells.

  2006cites this paper
• Interferon‐α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection

  2005cites this paper
• Interferons in the treatment of solid tumors.

  2005cites this paper
• The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells.

  2005cites this paper
• Enhanced expression of suppressor of cytokine signalling‐1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy

  2005cites this paper
• In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells

  2005cites this paper
• Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells

  2005cites this paper
• Overexpression of CR/periphilin downregulates Cdc7 expression and induces S-phase arrest.

  2004cites this paper
• Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells.

  2004cites this paper
• Interferon α‐induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming growth factor β1

  2004cites this paper
• Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo.

  2004cites this paper
• Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate.

  2004cites this paper
• Antiproliferative Effects of Interferon-αCon1 on Ovarian Clear Cell Adenocarcinoma In vitro and In vivo

  2004cites this paper
• Interferon alpha-induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming growth factor beta(1).

  2004cites this paper
• Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation

  2004cites this paper
• Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives

  2004cites this paper
• Randomized controlled trials on hepato-biliary-pancreatic surgery.

  2004cites this paper
• Reduced Expression of Epidermal Growth Factor Receptor-Related Protein in Hepatocellular Carcinoma: Implications for Cancer Growth

  2004cites this paper
• Inhibition of proliferation by 1-8U in interferon-α-responsive and non-responsive cell lines

  2003cites this paper
• Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours

  2003cites this paper
• Inhibition of proliferation by 1-8U in interferon-alpha-responsive and non-responsive cell lines.

  2003cites this paper
• IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat.

  2003cites this paper
• Exploring the Relationship Between Oral Health and Systemic Health Within the African American Population Enhancing Oral and Systemic Health 4

  2003cites this paper
• Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma.

  2003cites this paper
• Hepatitis C : A Critical Analysis of Therapeutic Response Predictors

  2003cites this paper
• Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.

  2003cites this paper
• Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses.

  2003cites this paper
• Nonsteroidal anti‐inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell‐cycle arrest

  2003cites this paper
• Interferon-alpha as an immunotherapeutic protein.

  2002cites this paper
• Synergistic induction of apoptosis by acyclic retinoid and interferon‐β in human hepatocellular carcinoma cells

  2002cites this paper
• Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes.

  2002cites this paper
• Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C

  2002cites this paper
• The in vivo apoptotic effect of interferon alfa‐2b on rat preneoplastic liver involves Bax protein

  2002cites this paper
• Interferon‐α as an immunotherapeutic protein

  2002cites this paper
• Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives

  2001cites this paper
• [New perspectives in the treatment of chronic hepatitis C].

  2001cites this paper
• Type I Interferons Differentially Modulate Autophagy to Shape Gemcitabine Response in Pancreatic Cancer Cells

  year unknowncites this paper